Herceptin® is approved for use in the United States (US), the European Union (EU), Japan, and much of the rest of the world for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer [1, 2], and is the standard of care for subjects with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer [3–5]. Here, ERBB2 is linked to breast carcinoma.